Find your next paid study

Onchilles Pharma IncNCT07339176

Observational

Accelerated Partial Breast Radiotherapy Study of a Personalized Holder for Prone Breast Immobilization to Enhance Local Delivery

The goal of this clinical trial is to find out whether using a personalized breast holder (called VENUS SHELL™) can improve positioning and patient comfort dur…

Invasive Breast Cancer Early StagesDuctal Carcinoma In Situ, DCIS

HeroSupport SANCT07711847

~$10 – $7,500

Phase 3

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more

Revolution Medicines, Inc.NCT07252232

Phase 1

A Phase 1 Study in Patients With Clinically Node-Positive Breast Cancer to Assess the Safety, Ultrasound Conspicuity, and Migration of an Optimized Ultrasound Twinkling Marker Observed for Sonographic Targeting (UTMOST2 Trial)

This phase I trial studies the performance, including ultrasound visibility, of an optimized ultrasound twinkling marker in imaging lymph nodes in patients wit…

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+1 more

Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer+2 more

Mayo ClinicNCT06999798

Phase 3

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received…

Olema Pharmaceuticals, Inc.NCT07085767

Phase 1

A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers wi…

Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult+8 more

Tyra Biosciences, IncNCT06915753

Advanced Hepatocellular CarcinomaAdvanced MelanomaLocally Advanced Melanoma+3 more

ADD-IT1: A Randomized Study of Adjuncts to Immunotherapy in Patients With Advanced Cancers

This clinical trial tests the effect of multiple therapies (propranolol, desloratadine, and magnesium and vitamin D supplements) added to primary standard of c…

University of Southern CaliforniaNCT07836712

Esophageal Squamous Cell Carcinoma

A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

This is a phase 2/window of opportunity study to determine the efficacy, by clinical complete response, and safety of induction toripalimab (PD-1 inhibitor) fo…

Vanderbilt-Ingram Cancer CenterNCT07836049

Central Nervous System Nongerminomatous Germ Cell TumorChoriocarcinomaEmbryonal Carcinoma+7 more

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in p…

Children's Oncology GroupNCT04684368

~$10 – $7,500

Phase 1

A Phase Ia/Ib Study of the Combination of the FGFR Inhibitor Pemigatinib and the EGFR Inhibitor Afatinib in Advanced Refractory Solid Tumors

This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid t…

Advanced Solid TumorUnresectable Solid TumorMetastatic Solid Tumor+1 more

Massachusetts General HospitalNCT06302621

Prostate AdenocarcinomaStage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8+1 more

Phase 2 Randomized Study to Assess Use of Androgen Deprivation to Enrich PSMA Expression and Improve Sensitivity of Staging PSMA PET/CT: The EnrichPSMA Trial

This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific me…

Mayo ClinicNCT07025369

Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compare…